Scholar Rock Holding Corp (SRRK) is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines to treat serious diseases in which signaling by protein growth factors plays a fundamental role. The company's proprietary technology platform enables the development of highly specific inhibitors of these signaling proteins, known as growth factor niche traps, to selectively block disease-causing signals.
SRRK's lead candidate is apitegromab (SRK-015), a selective inhibitor of the activation of myostatin, a protein that negatively regulates muscle growth. Apitegromab is being developed as a potential treatment for spinal muscular atrophy (SMA), a rare neuromuscular disease. SRRK is also advancing a pipeline of niche trap candidates for other serious diseases, including cancer, fibrosis, and anemia.
SRRK is headquartered in Cambridge, Massachusetts, and was founded in 2012. The company went public in 2018 and is traded on the NASDAQ stock exchange.
Scholar Rock Holding Corp (SRRK) is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines to treat serious diseases in which signaling by protein growth factors plays a fundamental role. The company's proprietary technology platform enables the development of highly specific inhibitors of these signaling proteins, known as growth factor niche traps, to selectively block disease-causing signals.